Low-Dose Naltrexone for Skin Picking Disorder
Low-dose naltrexone (LDN) at 1.5–4.5 mg daily can be used as an off-label treatment for skin-picking disorder (excoriation disorder), with dosing initiated at 1.5 mg at bedtime and titrated upward every 1-2 weeks to a maximum of 4.5 mg based on clinical response.
Mechanism and Rationale
LDN works through multiple pathways relevant to skin-picking disorder 1:
- Transiently blocks μ-opioid and κ-opioid receptors, leading to upregulation of endogenous opioid ligands and receptors
- Antagonizes toll-like receptor 4 (TLR-4), reducing pro-inflammatory cytokines and modulating microglial activity
- Decreases compulsive behaviors through modulation of the reward pathway
The evidence specifically supports LDN for body-focused repetitive behaviors, including skin-picking 2. One case report demonstrated clear improvement in excoriation disorder with LDN 4.5 mg, with temporal worsening when the medication was interrupted and improvement upon resumption 3.
Dosing Protocol
Starting dose: 1.5 mg at bedtime 1
Titration schedule: Increase by 1.5 mg every 1-2 weeks 1
Target dose: 4.5 mg at bedtime (maximum dose) 1
This differs substantially from standard naltrexone dosing for opioid/alcohol dependence (50 mg daily) 4. The low-dose range is critical—higher doses produce continuous receptor blockade, while low doses create intermittent blockade that paradoxically increases receptor expression and ligand activity 5.
Important Prescribing Considerations
Pre-Treatment Requirements
- Opioid-free period: Patients must be completely opioid-free (including tramadol) before starting, though this is less critical at low doses than at standard 50 mg dosing 4
- Screen for current opioid use—LDN will precipitate withdrawal in opioid-dependent patients
- No naloxone challenge test is needed for LDN dosing (unlike standard naltrexone) 1
Contraindications
- Active opioid use or dependence
- Acute hepatitis or liver failure
- Anticipated need for opioid analgesia (LDN blocks opioid effects)
Monitoring
Unlike standard-dose naltrexone, LDN does not require routine liver function monitoring at doses of 1.5-4.5 mg 1. However, baseline LFTs are reasonable, and periodic monitoring should occur if doses approach or exceed 50 mg 5.
Monitor for:
- Clinical response (reduction in picking frequency, lesion healing)
- Side effects (see below)
- Functional improvement in quality of life
Expected Timeline and Response
Clinical improvement typically occurs within 3 months of reaching therapeutic dose 3. The case report showed clear benefit at this timeframe, with worsening upon discontinuation demonstrating causality 3.
Response may include:
- Decreased compulsion to pick
- Improved healing of existing lesions
- Reduced frequency of picking episodes
Side Effects
LDN has a favorable side effect profile compared to standard naltrexone doses 2, 6:
Common (generally mild):
- Headache
- Vivid dreams or insomnia (reason for bedtime dosing)
- Tachycardia 1
Rare:
- Nausea (much less common than with standard doses)
- Anxiety or mood changes
Side effects are typically transient and resolve with continued use or dose adjustment 2.
Practical Barriers
Compounding requirement: LDN must be compounded by a pharmacy since commercial naltrexone is only available in 50 mg tablets 2. This creates:
- Access barriers in areas without compounding pharmacies
- Variable cost (typically $30-60/month out-of-pocket)
- Insurance coverage challenges (off-label use)
Integration with Other Treatments
LDN should be combined with behavioral interventions 7:
- Habit reversal therapy (awareness training and competing responses like fist-clenching) 8
- Cognitive-behavioral therapy
- Acceptance-enhanced behavior therapy
The combination of LDN with behavioral therapy addresses both the neurobiological and psychological components of skin-picking disorder.
Alternative Pharmacologic Options
If LDN is ineffective or unavailable, consider 7:
- N-acetylcysteine (1200-2400 mg daily)
- SSRIs (though evidence is mixed)
- Standard-dose naltrexone (50 mg daily)—requires more intensive monitoring for hepatotoxicity
Key Clinical Pitfalls
Don't use standard naltrexone dosing (50 mg) for skin-picking without considering LDN first—the side effect profile is worse and hepatotoxicity risk is higher 5
Don't forget the opioid-free requirement—even at low doses, naltrexone can precipitate withdrawal in opioid-dependent patients
Don't expect immediate results—allow 3 months at therapeutic dose before declaring treatment failure 3
Don't overlook compounding pharmacy logistics—identify a reliable compounding pharmacy before prescribing
Don't use LDN as monotherapy—always combine with behavioral interventions for optimal outcomes 7